These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21377425)

  • 1. Management of lower urinary tract dysfunction: a stepwise approach.
    Thom M; Campigotto M; Vemulakonda V; Coplen D; Austin PF
    J Pediatr Urol; 2012 Feb; 8(1):20-4. PubMed ID: 21377425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children.
    Franco I; Landau-Dyer L; Isom-Batz G; Collett T; Reda EF
    J Urol; 2007 Oct; 178(4 Pt 2):1775-9; discussion 1779-80. PubMed ID: 17707430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin type A in combination with standard urotherapy for children with dysfunctional voiding.
    Petronijevic V; Lazovic M; Vlajkovic M; Slavkovic A; Golubovic E; Miljkovic P
    J Urol; 2007 Dec; 178(6):2599-602; discussion 2602-3. PubMed ID: 17945299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipramine for refractory daytime incontinence in the pediatric population.
    Franco I; Arlen AM; Collett-Gardere T; Zelkovic PF
    J Pediatr Urol; 2018 Feb; 14(1):58.e1-58.e5. PubMed ID: 29100969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breaking the vicious circle: Onabotulinum toxin A in children with therapy-refractory dysfunctional voiding.
    't Hoen LA; van den Hoek J; Wolffenbuttel KP; van der Toorn F; Scheepe JR
    J Pediatr Urol; 2015 Jun; 11(3):119.e1-6. PubMed ID: 25794865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tamsulosin on systemic blood pressure and nonneurogenic dysfunctional voiding in children.
    Vanderbrink BA; Gitlin J; Toro S; Palmer LS
    J Urol; 2009 Feb; 181(2):817-22; discussion 822. PubMed ID: 19110267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial trial of timed voiding is warranted for all children with daytime incontinence.
    Allen HA; Austin JC; Boyt MA; Hawtrey CE; Cooper CS
    Urology; 2007 May; 69(5):962-5. PubMed ID: 17482943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?
    Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M
    Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of abnormal postvoid residual urine in children with dysfunctional voiding.
    Kibar Y; Piskin M; Irkilata HC; Aydur E; Gok F; Dayanc M
    Urology; 2010 Jun; 75(6):1472-5. PubMed ID: 19896172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-neurogenic lower urinary tract dysfunction].
    Skobejko-Włodarska L
    Pol Merkur Lekarski; 2008; 24 Suppl 4():131-7. PubMed ID: 18924526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urodynamic findings in children with cerebral palsy.
    Karaman MI; Kaya C; Caskurlu T; Guney S; Ergenekon E
    Int J Urol; 2005 Aug; 12(8):717-20. PubMed ID: 16174044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
    Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
    Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction.
    Kuo HC
    J Urol; 2003 Nov; 170(5):1908-12. PubMed ID: 14532805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder.
    Neel KF; Soliman S; Salem M; Seida M; Al-Hazmi H; Khatab A
    J Urol; 2007 Dec; 178(6):2593-7; discussion 2597-8. PubMed ID: 17945300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The aging lower urinary tract.
    Dubeau CE
    J Urol; 2006 Mar; 175(3 Pt 2):S11-5. PubMed ID: 16458733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Artificial urinary sphincter in children--voiding or emptying? An evaluation of functional results in 44 patients.
    Catti M; Lortat-Jacob S; Morineau M; Lottmann H
    J Urol; 2008 Aug; 180(2):690-3; discussion 693. PubMed ID: 18554645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha blocker therapy for children with dysfunctional voiding and urinary retention.
    Cain MP; Wu SD; Austin PF; Herndon CD; Rink RC
    J Urol; 2003 Oct; 170(4 Pt 2):1514-5; discussion 1516-7. PubMed ID: 14501648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of uroflow patterns in children with dysfunctional voiding.
    Wenske S; Van Batavia JP; Combs AJ; Glassberg KI
    J Pediatr Urol; 2014 Apr; 10(2):250-4. PubMed ID: 24290223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Animated biofeedback: an ideal treatment for children with dysfunctional elimination syndrome.
    Kajbafzadeh AM; Sharifi-Rad L; Ghahestani SM; Ahmadi H; Kajbafzadeh M; Mahboubi AH
    J Urol; 2011 Dec; 186(6):2379-84. PubMed ID: 22019033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.